Close Menu


Data presented at ASCO showing 76 percent of cancer patients responded to larotrectinib could lead to the availability of the first tissue-agnostic targeted drug.

The guidance includes recommendations for extended RAS mutation testing to guide anti-EGFR therapy, as well as updated endorsements for analysis of mismatch repair status.

The recommendations were developed by a working group of the AMP Clinical Practice Committee that included representatives from ACMG, ASCO, and CAP.

Eleven new recommendations were issued to address appropriate HER2 testing and clinical guidance in individuals with advanced gastroesophageal adenocarcinoma.

More groups are sharing genomic data, but barriers need to be addressed, according to a published paper and survey by the Global Alliance for Genomics and Health.

The results also showed that ctDNA as a marker of residual disease can help assess the efficacy of adjuvant therapy and improve the efficiency of clinical trials.

Looking beyond PD-L1 expression, investigators from several clinical trials considered a range of potential biomarkers for immune checkpoint treatment response.

The study involved the largest cohort to date, but uncertainty around less-studied, moderate-risk genes remains, experts said at ASCO's annual meeting.

Data from the meeting suggest that lung cancer patients with ALK-positive tumors may soon have two first-line options and more choices when their disease progresses.

Lynparza is just the start of an expansive portfolio of treatments targeting DNA damage response that AstraZeneca said it will advance with companion tests.